JP2003528810A - メラノコルチン−4受容体結合化合物及びその使用方法 - Google Patents
メラノコルチン−4受容体結合化合物及びその使用方法Info
- Publication number
- JP2003528810A JP2003528810A JP2001515309A JP2001515309A JP2003528810A JP 2003528810 A JP2003528810 A JP 2003528810A JP 2001515309 A JP2001515309 A JP 2001515309A JP 2001515309 A JP2001515309 A JP 2001515309A JP 2003528810 A JP2003528810 A JP 2003528810A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methoxy
- tetrahydro
- pyrimidine
- benzylsulfanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 436
- 238000000034 method Methods 0.000 title claims abstract description 292
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 title description 242
- 102000001796 Melanocortin 4 receptors Human genes 0.000 title 1
- 102100023724 Melanocortin receptor 4 Human genes 0.000 claims abstract description 89
- 230000004580 weight loss Effects 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 101710085775 Melanocortin receptor 4 Proteins 0.000 claims abstract 88
- -1 amino, amidino, guanidino Chemical group 0.000 claims description 718
- 125000000217 alkyl group Chemical group 0.000 claims description 257
- 125000003118 aryl group Chemical group 0.000 claims description 152
- 125000000623 heterocyclic group Chemical group 0.000 claims description 112
- 125000003342 alkenyl group Chemical group 0.000 claims description 109
- 125000000304 alkynyl group Chemical group 0.000 claims description 104
- 125000003545 alkoxy group Chemical group 0.000 claims description 92
- 239000001257 hydrogen Substances 0.000 claims description 92
- 229910052739 hydrogen Inorganic materials 0.000 claims description 92
- 229910052736 halogen Inorganic materials 0.000 claims description 90
- 150000002367 halogens Chemical class 0.000 claims description 84
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 76
- 229910052799 carbon Inorganic materials 0.000 claims description 71
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 56
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 55
- 229910052717 sulfur Inorganic materials 0.000 claims description 52
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 50
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 50
- 241000124008 Mammalia Species 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 46
- 150000001721 carbon Chemical group 0.000 claims description 46
- 125000001424 substituent group Chemical group 0.000 claims description 46
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 125000002252 acyl group Chemical group 0.000 claims description 42
- 229910052760 oxygen Inorganic materials 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 40
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 39
- 125000004122 cyclic group Chemical group 0.000 claims description 39
- 125000001624 naphthyl group Chemical group 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 32
- 239000001301 oxygen Substances 0.000 claims description 32
- 239000011593 sulfur Substances 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 30
- 239000000460 chlorine Substances 0.000 claims description 30
- 229910052801 chlorine Inorganic materials 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 29
- 239000011737 fluorine Substances 0.000 claims description 28
- 229910052731 fluorine Inorganic materials 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 27
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 27
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 26
- 229910052794 bromium Inorganic materials 0.000 claims description 26
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 25
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 150000005347 biaryls Chemical group 0.000 claims description 20
- 125000004429 atom Chemical group 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 16
- 125000005647 linker group Chemical group 0.000 claims description 16
- SBOJXQVPLKSXOG-UHFFFAOYSA-N o-amino-hydroxylamine Chemical class NON SBOJXQVPLKSXOG-UHFFFAOYSA-N 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 15
- 208000016261 weight loss Diseases 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 13
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 206010006895 Cachexia Diseases 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 12
- 229910014033 C-OH Inorganic materials 0.000 claims description 11
- 229910014570 C—OH Inorganic materials 0.000 claims description 11
- 125000003367 polycyclic group Chemical group 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 150000003568 thioethers Chemical class 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- KWBJMDZAPHKDFB-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]piperidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCCCC1 KWBJMDZAPHKDFB-UHFFFAOYSA-N 0.000 claims description 8
- DYASGHCSJCHRAM-UHFFFAOYSA-N 1-[[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(F)=CC=CC=1CN1CCNCC1 DYASGHCSJCHRAM-UHFFFAOYSA-N 0.000 claims description 8
- QRDFGAHATXGIBR-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methoxy]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1COC1=CC=CC=C1C1=NCCCN1 QRDFGAHATXGIBR-UHFFFAOYSA-N 0.000 claims description 8
- VBUILYKEAPKRKE-UHFFFAOYSA-N 2-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CC1=NCCCN1 VBUILYKEAPKRKE-UHFFFAOYSA-N 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 8
- GLGIWLZTKPEBKS-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-6-ethyl-1,4,5,6-tetrahydropyrimidine Chemical compound N1C(CC)CCN=C1C1=CC=CC=C1SCC1=CC(Br)=CC=C1OC GLGIWLZTKPEBKS-UHFFFAOYSA-N 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000002619 bicyclic group Chemical group 0.000 claims description 7
- XYZDDOTYDXXWPM-UHFFFAOYSA-N n-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]-n-ethylethanamine Chemical compound CCN(CC)CC1=CC=CC=C1SCC1=CC(Br)=CC=C1OC XYZDDOTYDXXWPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 6
- 230000019612 pigmentation Effects 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 5
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- SHZPSAKOOSXLBB-UHFFFAOYSA-N 1-(naphthalen-1-ylmethyl)-3-(2-phenylethyl)-1-(2-piperidin-1-ylethyl)thiourea Chemical compound C1CCCCN1CCN(CC=1C2=CC=CC=C2C=CC=1)C(=S)NCCC1=CC=CC=C1 SHZPSAKOOSXLBB-UHFFFAOYSA-N 0.000 claims description 4
- GIHQQJIHBAIGSO-UHFFFAOYSA-N 1-[2-(2-naphthalen-1-ylethyl)phenyl]ethane-1,2-diamine Chemical compound NCC(N)C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 GIHQQJIHBAIGSO-UHFFFAOYSA-N 0.000 claims description 4
- ATZDPWOFOKHOFM-UHFFFAOYSA-N 1-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN(C)C ATZDPWOFOKHOFM-UHFFFAOYSA-N 0.000 claims description 4
- RCAPUOMCNFOSTP-UHFFFAOYSA-N 1-[4-methoxy-3-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]phenyl]ethanone Chemical compound COC1=CC=C(C(C)=O)C=C1CSC1=CC=CC=C1C1=NCCCN1 RCAPUOMCNFOSTP-UHFFFAOYSA-N 0.000 claims description 4
- UPUQOEPOWHSGPH-UHFFFAOYSA-N 1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC1=CC=CC=C1CN1CCNCC1 UPUQOEPOWHSGPH-UHFFFAOYSA-N 0.000 claims description 4
- UWBWBCKISPTABJ-UHFFFAOYSA-N 1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 UWBWBCKISPTABJ-UHFFFAOYSA-N 0.000 claims description 4
- IILSKIZWMSVWAI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]piperazine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCNCC1 IILSKIZWMSVWAI-UHFFFAOYSA-N 0.000 claims description 4
- SYACJNJDWOFLPR-UHFFFAOYSA-N 2-(2-benzylsulfanylphenyl)-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=CC=1CSC1=CC=CC=C1C1=NCCCN1 SYACJNJDWOFLPR-UHFFFAOYSA-N 0.000 claims description 4
- KGUYGXACOPYBBV-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-(1,4,5,6-tetrahydropyrimidin-2-yl)pyrazine Chemical compound COC1=CC=C(Br)C=C1CSC1=NC=CN=C1C1=NCCCN1 KGUYGXACOPYBBV-UHFFFAOYSA-N 0.000 claims description 4
- SVPBPRSLWASWKI-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-piperazin-1-yl-6,7-dihydroquinoxaline Chemical compound COC1=CC=C(Br)C=C1CSC1=NC2=CCCC=C2N=C1N1CCNCC1 SVPBPRSLWASWKI-UHFFFAOYSA-N 0.000 claims description 4
- SCCAFPIBEOBGTQ-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]benzenecarboximidamide Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C(N)=N SCCAFPIBEOBGTQ-UHFFFAOYSA-N 0.000 claims description 4
- ACJPYKJBCKVDIV-UHFFFAOYSA-N 2-[2-(2-naphthalen-1-ylethyl)-3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(C(F)(F)F)=CC=CC=1C1=NCCCN1 ACJPYKJBCKVDIV-UHFFFAOYSA-N 0.000 claims description 4
- RTLGWGUKVAYFGQ-UHFFFAOYSA-N 2-[2-(2-naphthalen-1-ylethyl)phenyl]ethanamine Chemical compound NCCC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 RTLGWGUKVAYFGQ-UHFFFAOYSA-N 0.000 claims description 4
- HQKSAFODQJVAMY-UHFFFAOYSA-N 2-[2-(9h-fluoren-9-ylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCNC(C=2C(=CC=CC=2)SC2C3=CC=CC=C3C3=CC=CC=C32)=N1 HQKSAFODQJVAMY-UHFFFAOYSA-N 0.000 claims description 4
- ZLJUCWCUFIZEDW-UHFFFAOYSA-N 2-[2-[(2,5-dichlorophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=C(Cl)C(SCC=2C(=CC=CC=2)C=2NCCCN=2)=C1 ZLJUCWCUFIZEDW-UHFFFAOYSA-N 0.000 claims description 4
- USWIGGWFARNAIT-UHFFFAOYSA-N 2-[2-[(2,5-dimethylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=C(C)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 USWIGGWFARNAIT-UHFFFAOYSA-N 0.000 claims description 4
- IIXSESNTPZDVOB-UHFFFAOYSA-N 2-[2-[(2,6-difluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC(F)=C1CSC1=CC=CC=C1C1=NCCCN1 IIXSESNTPZDVOB-UHFFFAOYSA-N 0.000 claims description 4
- IKNWNXHMEIPMHN-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 IKNWNXHMEIPMHN-UHFFFAOYSA-N 0.000 claims description 4
- HNKHRELQAZCOCP-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C1=NCCN1 HNKHRELQAZCOCP-UHFFFAOYSA-N 0.000 claims description 4
- KTWWZGRWSAZNFV-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C1=NCCCN1 KTWWZGRWSAZNFV-UHFFFAOYSA-N 0.000 claims description 4
- YSKONJARCLBXRG-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 YSKONJARCLBXRG-UHFFFAOYSA-N 0.000 claims description 4
- XROZEKFUKUQTAT-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=CC=CC=C1C1=NCCN1 XROZEKFUKUQTAT-UHFFFAOYSA-N 0.000 claims description 4
- JURFLFGQSHDRQR-UHFFFAOYSA-N 2-[2-[(2-propan-2-yloxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC(C)OC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 JURFLFGQSHDRQR-UHFFFAOYSA-N 0.000 claims description 4
- PUDQPIKMLRFZPN-UHFFFAOYSA-N 2-[2-[(5-bromo-2-cyclopentyloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(C=2NCCCN=2)C=1SCC1=CC(Br)=CC=C1OC1CCCC1 PUDQPIKMLRFZPN-UHFFFAOYSA-N 0.000 claims description 4
- GPSOQGAPPIJCEG-UHFFFAOYSA-N 2-[2-[(5-bromo-2-ethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCOC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 GPSOQGAPPIJCEG-UHFFFAOYSA-N 0.000 claims description 4
- CPJWCFKQCQUQLI-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methoxymethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1COCC1=CC=CC=C1C1=NCCCN1 CPJWCFKQCQUQLI-UHFFFAOYSA-N 0.000 claims description 4
- RGMPFJUALNCLIZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,4-difluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C(F)=CC=C1C1=NCCCN1 RGMPFJUALNCLIZ-UHFFFAOYSA-N 0.000 claims description 4
- BHRKIYVQKAPXBH-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,5-difluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=C(F)C=C1C1=NCCCN1 BHRKIYVQKAPXBH-UHFFFAOYSA-N 0.000 claims description 4
- BVRSBCUMISUFPR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidin-5-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NCC(O)CN1 BVRSBCUMISUFPR-UHFFFAOYSA-N 0.000 claims description 4
- ORJVHEZQRTWNPN-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NCCCN1 ORJVHEZQRTWNPN-UHFFFAOYSA-N 0.000 claims description 4
- LNPRXFXPBRCTGB-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NC(C)CN1 LNPRXFXPBRCTGB-UHFFFAOYSA-N 0.000 claims description 4
- VFXNWSNBKZPTTD-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]guanidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1NC(N)=N VFXNWSNBKZPTTD-UHFFFAOYSA-N 0.000 claims description 4
- DIHXBZVYCWIMIW-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=C(Cl)C=CC=C1C1=NCCCN1 DIHXBZVYCWIMIW-UHFFFAOYSA-N 0.000 claims description 4
- FYSBRELZWWDOLV-UHFFFAOYSA-N 2-[2-[(6-bromo-2-methoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=C(Br)C=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 FYSBRELZWWDOLV-UHFFFAOYSA-N 0.000 claims description 4
- XZTTZBZEQYPTEC-UHFFFAOYSA-N 2-[2-[(6-methoxy-2,3-dihydro-1,4-benzodioxin-5-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2OCCOC2=C1CSC1=CC=CC=C1C1=NCCCN1 XZTTZBZEQYPTEC-UHFFFAOYSA-N 0.000 claims description 4
- UCANUPCLAHKJLU-UHFFFAOYSA-N 2-[2-[2-(2,3-dihydro-1,4-benzodioxin-5-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=2OCCOC=2C=1CCC1=CC=CC=C1C1=NCCCN1 UCANUPCLAHKJLU-UHFFFAOYSA-N 0.000 claims description 4
- WMSIKZDVBSROMD-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=CC=CC=C1C1=NCCCN1 WMSIKZDVBSROMD-UHFFFAOYSA-N 0.000 claims description 4
- SNXCNGBBNPGLHD-UHFFFAOYSA-N 2-[3-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]thiophen-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC=1C=CSC=1C1=NCCCN1 SNXCNGBBNPGLHD-UHFFFAOYSA-N 0.000 claims description 4
- HUQNTTQVZYURMS-UHFFFAOYSA-N 2-[3-[(5-bromo-2-methoxyphenyl)methylsulfanyl]pyridin-2-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CN=C1C1=NCCCN1 HUQNTTQVZYURMS-UHFFFAOYSA-N 0.000 claims description 4
- ONZWKMMEAIYJPY-UHFFFAOYSA-N 2-[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound N1C(C)(C)CN=C1C1=CC=CC(F)=C1CCC1=CC=CC2=CC=CC=C12 ONZWKMMEAIYJPY-UHFFFAOYSA-N 0.000 claims description 4
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- YUPITEIZSJWQJT-UHFFFAOYSA-N 2-piperidin-1-ylethyl n-[2-[(2-methylnaphthalen-1-yl)methylsulfanyl]phenyl]carbamate Chemical compound CC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1NC(=O)OCCN1CCCCC1 YUPITEIZSJWQJT-UHFFFAOYSA-N 0.000 claims description 4
- QAAXFJDGBDRGRQ-UHFFFAOYSA-N 3-[4-(dimethylamino)phenyl]-1-[3-(dimethylamino)propyl]-1-(naphthalen-1-ylmethyl)thiourea Chemical compound C=1C=CC2=CC=CC=C2C=1CN(CCCN(C)C)C(=S)NC1=CC=C(N(C)C)C=C1 QAAXFJDGBDRGRQ-UHFFFAOYSA-N 0.000 claims description 4
- IVLLVRGXVQYAEQ-UHFFFAOYSA-N 4-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]morpholine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CCOCC1 IVLLVRGXVQYAEQ-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 4
- JMVNFIOCAYFCIY-UHFFFAOYSA-N [2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methanamine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN JMVNFIOCAYFCIY-UHFFFAOYSA-N 0.000 claims description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- RHZAFXCZRSNAJI-UHFFFAOYSA-N ethyl 4-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methylamino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1NCC1=CC=CC(Cl)=C1SCC1=CC(Br)=CC=C1OC RHZAFXCZRSNAJI-UHFFFAOYSA-N 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- TWKUKZOQMKBOKB-UHFFFAOYSA-N methyl 1-(2-naphthalen-1-ylethyl)piperidine-2-carboxylate Chemical compound COC(=O)C1CCCCN1CCC1=CC=CC2=CC=CC=C12 TWKUKZOQMKBOKB-UHFFFAOYSA-N 0.000 claims description 4
- SLCAGYISQJNUGD-UHFFFAOYSA-N n-[[1-(2-naphthalen-1-ylethyl)pyrrolidin-2-yl]methyl]-1h-pyrrol-2-amine Chemical compound C=1C=CC2=CC=CC=C2C=1CCN1CCCC1CNC1=CC=CN1 SLCAGYISQJNUGD-UHFFFAOYSA-N 0.000 claims description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 4
- DHMLFLUIIOQLOJ-UHFFFAOYSA-N 1,3-di(piperidin-1-yl)propan-2-yl n-(2-hexoxyphenyl)carbamate Chemical compound CCCCCCOC1=CC=CC=C1NC(=O)OC(CN1CCCCC1)CN1CCCCC1 DHMLFLUIIOQLOJ-UHFFFAOYSA-N 0.000 claims description 3
- RGFBAGOHQXOXRY-UHFFFAOYSA-N 1,3-di(piperidin-1-yl)propan-2-yl n-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamate Chemical compound C=1C=CC=C(SCC=2C3=CC=CC=C3C=CC=2)C=1NC(=O)OC(CN1CCCCC1)CN1CCCCC1 RGFBAGOHQXOXRY-UHFFFAOYSA-N 0.000 claims description 3
- GAZFMSFTOKVZQL-UHFFFAOYSA-N 1-(1-ethylpyrrolidin-2-yl)-n-(naphthalen-1-ylmethyl)-n-(naphthalen-2-ylmethyl)methanamine Chemical compound CCN1CCCC1CN(CC=1C2=CC=CC=C2C=CC=1)CC1=CC=C(C=CC=C2)C2=C1 GAZFMSFTOKVZQL-UHFFFAOYSA-N 0.000 claims description 3
- QCIYTUBLCHCWKF-UHFFFAOYSA-N 1-[3-[(5-bromo-2-methoxyphenyl)methylsulfanyl]pyrazin-2-yl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=NC=CN=C1N1CC(N)CC1 QCIYTUBLCHCWKF-UHFFFAOYSA-N 0.000 claims description 3
- WODPAVGRLDMTGA-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]-2-(methoxymethyl)pyrrolidine Chemical compound COCC1CCCN1CC1=CC=CC(Cl)=C1SCC1=CC(Br)=CC=C1OC WODPAVGRLDMTGA-UHFFFAOYSA-N 0.000 claims description 3
- JMUUYBCFUZIXOY-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]azetidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CCC1 JMUUYBCFUZIXOY-UHFFFAOYSA-N 0.000 claims description 3
- NDPLIKQZAAIEAD-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]piperazine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CCNCC1 NDPLIKQZAAIEAD-UHFFFAOYSA-N 0.000 claims description 3
- AWVJYNDPVRJZQI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CC(N)CC1 AWVJYNDPVRJZQI-UHFFFAOYSA-N 0.000 claims description 3
- IFCDMRMMCXRJEV-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]pyrrolidin-3-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CN1CC(O)CC1 IFCDMRMMCXRJEV-UHFFFAOYSA-N 0.000 claims description 3
- IKYPYTQRZDPPLI-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CC(N)CC1 IKYPYTQRZDPPLI-UHFFFAOYSA-N 0.000 claims description 3
- WOAQXXVCKUXXIM-UHFFFAOYSA-N 1-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methyl]pyrrolidin-3-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CN1CC(O)CC1 WOAQXXVCKUXXIM-UHFFFAOYSA-N 0.000 claims description 3
- LPFIAUCSSYOSJI-UHFFFAOYSA-N 2-(2-benzhydrylsulfanylphenyl)-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCNC(C=2C(=CC=CC=2)SC(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 LPFIAUCSSYOSJI-UHFFFAOYSA-N 0.000 claims description 3
- DLZFOGIKAJESJI-UHFFFAOYSA-N 2-[2-(1-naphthalen-1-ylethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)SC1=CC=CC=C1C1=NCCCN1 DLZFOGIKAJESJI-UHFFFAOYSA-N 0.000 claims description 3
- FWPVLIBLPJCPKP-UHFFFAOYSA-N 2-[2-(2,3-dihydro-1,4-benzodioxin-5-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=2OCCOC=2C=1CSC1=CC=CC=C1C1=NCCCN1 FWPVLIBLPJCPKP-UHFFFAOYSA-N 0.000 claims description 3
- HLXFXORVYDASPB-UHFFFAOYSA-N 2-[2-(cyclohexylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCCCC1CSC1=CC=CC=C1C1=NCCCN1 HLXFXORVYDASPB-UHFFFAOYSA-N 0.000 claims description 3
- QDZMJIFWBKCDIU-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylmethoxy)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1COC1=CC=CC=C1C1=NCCCN1 QDZMJIFWBKCDIU-UHFFFAOYSA-N 0.000 claims description 3
- WUXIBNPXDCPMEH-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 WUXIBNPXDCPMEH-UHFFFAOYSA-N 0.000 claims description 3
- FIZAQPWFWADZQW-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1=NCCCN1 FIZAQPWFWADZQW-UHFFFAOYSA-N 0.000 claims description 3
- PTYYJYFKWLYTJJ-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1=NCCN1 PTYYJYFKWLYTJJ-UHFFFAOYSA-N 0.000 claims description 3
- WWNCZFPVXCKTNW-UHFFFAOYSA-N 2-[2-[(2,5-dimethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(OC)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 WWNCZFPVXCKTNW-UHFFFAOYSA-N 0.000 claims description 3
- SUSFCKRSJXFKFJ-UHFFFAOYSA-N 2-[2-[(2,5-dimethoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(OC)C(SCC=2C(=CC=CC=2)C=2NCCCN=2)=C1 SUSFCKRSJXFKFJ-UHFFFAOYSA-N 0.000 claims description 3
- JCBIOHYTOHEEKN-UHFFFAOYSA-N 2-[2-[(2-chlorophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound ClC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 JCBIOHYTOHEEKN-UHFFFAOYSA-N 0.000 claims description 3
- UEYAWOPDBOWKEK-UHFFFAOYSA-N 2-[2-[(2-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 UEYAWOPDBOWKEK-UHFFFAOYSA-N 0.000 claims description 3
- JLIDYMPVMLNLGY-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-nitrophenyl)methylsulfanyl]pyridin-3-yl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C([N+]([O-])=O)C=C1CSC1=NC=CC=C1C1=NCCCN1 JLIDYMPVMLNLGY-UHFFFAOYSA-N 0.000 claims description 3
- QRISVWPWDXQJMG-UHFFFAOYSA-N 2-[2-[(2-methoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 QRISVWPWDXQJMG-UHFFFAOYSA-N 0.000 claims description 3
- YZQSLUVOBLBNMG-UHFFFAOYSA-N 2-[2-[(3,5-dimethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC(OC)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 YZQSLUVOBLBNMG-UHFFFAOYSA-N 0.000 claims description 3
- YQXGBUCFRQYHMD-UHFFFAOYSA-N 2-[2-[(3-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 YQXGBUCFRQYHMD-UHFFFAOYSA-N 0.000 claims description 3
- KWBUUMUFWHBVGS-UHFFFAOYSA-N 2-[2-[(4-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1=CC(F)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 KWBUUMUFWHBVGS-UHFFFAOYSA-N 0.000 claims description 3
- DRCKIXIPSQZHTF-UHFFFAOYSA-N 2-[2-[(4-phenylmethoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=CC=1COC(C=C1)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 DRCKIXIPSQZHTF-UHFFFAOYSA-N 0.000 claims description 3
- DHGHRXKJJOANFR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1C1=NC(C)CN1 DHGHRXKJJOANFR-UHFFFAOYSA-N 0.000 claims description 3
- WHXSLNWBYOEZBI-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluoro-4-(trifluoromethyl)phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C(C(F)(F)F)=CC=C1C1=NC(C)(C)CN1 WHXSLNWBYOEZBI-UHFFFAOYSA-N 0.000 claims description 3
- QMSDCVRXVFCLRL-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 QMSDCVRXVFCLRL-UHFFFAOYSA-N 0.000 claims description 3
- CXKQSXANCQVLRO-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=C(F)C=CC=C1C1=NCCCN1 CXKQSXANCQVLRO-UHFFFAOYSA-N 0.000 claims description 3
- DSRUBXVCPSJSAX-UHFFFAOYSA-N 2-[2-[2-(2-methylnaphthalen-1-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=C2C=CC=CC2=C1CCC1=CC=CC=C1C1=NCCCN1 DSRUBXVCPSJSAX-UHFFFAOYSA-N 0.000 claims description 3
- XFWBPYOQWBEJDY-UHFFFAOYSA-N 2-[3-chloro-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(Cl)=CC=CC=1C1=NCCCN1 XFWBPYOQWBEJDY-UHFFFAOYSA-N 0.000 claims description 3
- VQPNUOOVVQVJAQ-UHFFFAOYSA-N 2-[3-fluoro-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(F)=CC=CC=1C1=NCCCN1 VQPNUOOVVQVJAQ-UHFFFAOYSA-N 0.000 claims description 3
- WWQPTDNNDBFOLF-UHFFFAOYSA-N 2-[3-methoxy-2-(2-naphthalen-1-ylethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CCC=1C(OC)=CC=CC=1C1=NCCCN1 WWQPTDNNDBFOLF-UHFFFAOYSA-N 0.000 claims description 3
- REYLZFXVSGOFRG-UHFFFAOYSA-N 2-[4-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC(C=C1)=CC=C1C1=NCCCN1 REYLZFXVSGOFRG-UHFFFAOYSA-N 0.000 claims description 3
- HLMAGOZCRZZHQE-UHFFFAOYSA-N 3-imidazol-1-yl-n-(naphthalen-1-ylmethyl)-n-(naphthalen-2-ylmethyl)propan-1-amine Chemical compound C=1C=C2C=CC=CC2=CC=1CN(CC=1C2=CC=CC=C2C=CC=1)CCCN1C=CN=C1 HLMAGOZCRZZHQE-UHFFFAOYSA-N 0.000 claims description 3
- XWXDYXQSASHOQE-UHFFFAOYSA-N 4-methoxy-3-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]benzonitrile Chemical compound COC1=CC=C(C#N)C=C1CSC1=CC=CC=C1C1=NCCCN1 XWXDYXQSASHOQE-UHFFFAOYSA-N 0.000 claims description 3
- 229940126661 MC4 antagonist Drugs 0.000 claims description 3
- 241000051616 Ulmus minor Species 0.000 claims description 3
- DBIZGVXQPFDTDA-UHFFFAOYSA-N [1-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 DBIZGVXQPFDTDA-UHFFFAOYSA-N 0.000 claims description 3
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- WHPBDZMNGAVUPV-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]-1-(1-ethylpyrrolidin-2-yl)-n-(naphthalen-1-ylmethyl)methanamine Chemical compound CCN1CCCC1CN(CC=1C2=CC=CC=C2C=CC=1)CC1=CC=CC(Br)=C1 WHPBDZMNGAVUPV-UHFFFAOYSA-N 0.000 claims description 3
- RTHMKHFTQFJYGA-UHFFFAOYSA-N n-[(5-bromo-2-methoxyphenyl)methyl]-n-methyl-2-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound COC1=CC=C(Br)C=C1CN(C)C1=CC=CC=C1C1=NCCCN1 RTHMKHFTQFJYGA-UHFFFAOYSA-N 0.000 claims description 3
- IUUWYNSTWKOEJX-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-(naphthalen-1-ylmethyl)naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N(CC=3C4=CC=CC=C4C=CC=3)CCN(C)C)=CC=C21 IUUWYNSTWKOEJX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000003003 spiro group Chemical group 0.000 claims description 3
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- ANFXTILBDGTSEG-UHFFFAOYSA-N 1-methyl-4,5-dihydroimidazole Chemical group CN1CCN=C1 ANFXTILBDGTSEG-UHFFFAOYSA-N 0.000 claims 2
- SMTXSQTYIZFVIR-UHFFFAOYSA-N 2-[2-[(2-cyclopentyloxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1CCCC1OC=1C=CC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 SMTXSQTYIZFVIR-UHFFFAOYSA-N 0.000 claims 2
- IZUJSZAYULSQCW-UHFFFAOYSA-N 2-[2-[(2-iodophenyl)methylsulfanyl]phenyl]-3a,4,5,6,7,7a-hexahydro-1h-benzimidazole Chemical compound IC1=CC=CC=C1CSC1=CC=CC=C1C(N1)=NC2C1CCCC2 IZUJSZAYULSQCW-UHFFFAOYSA-N 0.000 claims 2
- VUQUNQSDLBZMCT-UHFFFAOYSA-N 2-[2-[(2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC=C1CSC1=CC=CC=C1C1=NCCCN1 VUQUNQSDLBZMCT-UHFFFAOYSA-N 0.000 claims 2
- UPQADLLHDZSLHC-UHFFFAOYSA-N CC(C=C1)=CC(CSC(C=CC=C2)=C2N2C=NCCC2)=C1OC Chemical compound CC(C=C1)=CC(CSC(C=CC=C2)=C2N2C=NCCC2)=C1OC UPQADLLHDZSLHC-UHFFFAOYSA-N 0.000 claims 2
- QIJLUZAUEGPNIB-UHFFFAOYSA-N n'-[(5-bromo-2-methoxyphenyl)methyl]-n,n-dimethyl-n'-(naphthalen-1-ylmethyl)propane-1,3-diamine Chemical compound COC1=CC=C(Br)C=C1CN(CCCN(C)C)CC1=CC=CC2=CC=CC=C12 QIJLUZAUEGPNIB-UHFFFAOYSA-N 0.000 claims 2
- AZJXYSILXBMBDR-UHFFFAOYSA-N n,n-dimethyl-n'-(naphthalen-1-ylmethyl)-n'-(naphthalen-2-ylmethyl)propane-1,3-diamine Chemical compound C1=CC=C2C(CN(CC=3C=C4C=CC=CC4=CC=3)CCCN(C)C)=CC=CC2=C1 AZJXYSILXBMBDR-UHFFFAOYSA-N 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- FGYBDASKYMSNCX-UHFFFAOYSA-N 2,5-dichlorothiophene Chemical compound ClC1=CC=C(Cl)S1 FGYBDASKYMSNCX-UHFFFAOYSA-N 0.000 claims 1
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 1
- HFYUGPNUTBOKQF-UHFFFAOYSA-N 6-piperazin-1-yl-7-(trifluoromethyl)thieno[3,2-b]pyridine-3-carboxylic acid Chemical compound C=1N=C2C(C(=O)O)=CSC2=C(C(F)(F)F)C=1N1CCNCC1 HFYUGPNUTBOKQF-UHFFFAOYSA-N 0.000 claims 1
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 claims 1
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 claims 1
- 229950007538 pecazine Drugs 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 150000005326 tetrahydropyrimidines Chemical class 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 8
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 242
- 210000004027 cell Anatomy 0.000 description 36
- 125000003282 alkyl amino group Chemical group 0.000 description 30
- 125000001769 aryl amino group Chemical group 0.000 description 26
- 229910019142 PO4 Inorganic materials 0.000 description 24
- 125000004442 acylamino group Chemical group 0.000 description 24
- 125000004414 alkyl thio group Chemical group 0.000 description 24
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 24
- 239000010452 phosphate Substances 0.000 description 24
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 23
- 235000019000 fluorine Nutrition 0.000 description 23
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 22
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 22
- 125000005110 aryl thio group Chemical group 0.000 description 22
- 235000017168 chlorine Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 22
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 21
- 125000004986 diarylamino group Chemical group 0.000 description 21
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 20
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 20
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 20
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 20
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 19
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 17
- 150000007942 carboxylates Chemical class 0.000 description 17
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 16
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 229940124530 sulfonamide Drugs 0.000 description 14
- 150000003456 sulfonamides Chemical class 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 125000002877 alkyl aryl group Chemical group 0.000 description 12
- 150000001540 azides Chemical class 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000002821 scintillation proximity assay Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 108010008364 Melanocortins Proteins 0.000 description 10
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 10
- 125000005129 aryl carbonyl group Chemical group 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000003573 thiols Chemical class 0.000 description 10
- 102000004378 Melanocortin Receptors Human genes 0.000 description 9
- 108090000950 Melanocortin Receptors Proteins 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 229960005141 piperazine Drugs 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229960004793 sucrose Drugs 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000002865 melanocortin Substances 0.000 description 7
- 125000002757 morpholinyl group Chemical group 0.000 description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- 102100023723 Melanocortin receptor 5 Human genes 0.000 description 6
- 101710085771 Melanocortin receptor 5 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 6
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 5
- 101710161100 Melanocyte-stimulating hormone receptor Proteins 0.000 description 5
- 241001024304 Mino Species 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- IGCCPAKERWHUNZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1SCC1=CC=CC=C1C1=NCCCN1 IGCCPAKERWHUNZ-UHFFFAOYSA-N 0.000 description 4
- 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 4
- 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000005300 thiocarboxy group Chemical group C(=S)(O)* 0.000 description 4
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- YXBXWTPGDOGXMJ-UHFFFAOYSA-N (2-hexoxyphenyl)carbamic acid Chemical compound CCCCCCOC1=CC=CC=C1NC(O)=O YXBXWTPGDOGXMJ-UHFFFAOYSA-N 0.000 description 3
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical group C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100023726 Melanocortin receptor 3 Human genes 0.000 description 3
- 101710085774 Melanocortin receptor 3 Proteins 0.000 description 3
- 102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 3
- 101710129905 Melanotropin beta Proteins 0.000 description 3
- 241001553014 Myrsine salicina Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 2
- ZACLFWISXHXZSS-UHFFFAOYSA-N 1-(6-bromo-2-chloroquinolin-4-yl)-3-[2-(diethylamino)ethyl]urea Chemical compound C1=C(Br)C=C2C(NC(=O)NCCN(CC)CC)=CC(Cl)=NC2=C1 ZACLFWISXHXZSS-UHFFFAOYSA-N 0.000 description 2
- WSXOKTKQMKXUKK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-[(2-methylnaphthalen-1-yl)methylsulfanyl]phenyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1=CC=CC=C1SCC1=C2C=CC=CC2=CC=C1C WSXOKTKQMKXUKK-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- LVGIUOZGDVZIMK-UHFFFAOYSA-N 1-sulfanylpyrrolidine Chemical compound SN1CCCC1 LVGIUOZGDVZIMK-UHFFFAOYSA-N 0.000 description 2
- YQQSRZSUGBETRS-UHFFFAOYSA-N 1h-pyridazine-6-thione Chemical compound SC1=CC=CN=N1 YQQSRZSUGBETRS-UHFFFAOYSA-N 0.000 description 2
- QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 2
- KKWGREIGMAWSGA-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-methylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C)C=C1CSC1=CC=CC=C1C1=NCCCN1 KKWGREIGMAWSGA-UHFFFAOYSA-N 0.000 description 2
- HJWLUEOYGAIIGV-UHFFFAOYSA-N 2-[2-[(5-iodo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(I)C=C1CSC1=CC=CC=C1C1=NCCCN1 HJWLUEOYGAIIGV-UHFFFAOYSA-N 0.000 description 2
- NAPYCAWRLDPGFK-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(2-phenylethynyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C#CC=2C=CC=CC=2)C=C1CSC1=CC=CC=C1C1=NCCCN1 NAPYCAWRLDPGFK-UHFFFAOYSA-N 0.000 description 2
- OXYGFGRBQBBYLQ-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C(F)(F)F)C=C1CSC1=CC=CC=C1C1=NCCCN1 OXYGFGRBQBBYLQ-UHFFFAOYSA-N 0.000 description 2
- OQQKRORCCALBOF-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)-n-[[2-(2-naphthalen-1-ylethyl)phenyl]methyl]propan-1-amine Chemical compound CC1CCCCN1CCCNCC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 OQQKRORCCALBOF-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 102000017351 Melanocortin 3 receptors Human genes 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- 101100129532 Mus musculus Mc4r gene Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 description 2
- 108010021433 Type 3 Melanocortin Receptor Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- RWRGOKPWZKWGMF-UHFFFAOYSA-N [2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid Chemical compound OC(=O)NC1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 RWRGOKPWZKWGMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229960002312 tolazoline Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- FRFKCMNQNNNZNO-UHFFFAOYSA-N 1-[3-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound FC(F)(F)C1=CC=CN=C1N1CCNCC1 FRFKCMNQNNNZNO-UHFFFAOYSA-N 0.000 description 1
- BNMSJUIMZULLAS-UHFFFAOYSA-N 1-[5-(trifluoromethyl)pyridin-2-yl]piperazine Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCNCC1 BNMSJUIMZULLAS-UHFFFAOYSA-N 0.000 description 1
- BCQNKADIWADQCL-UHFFFAOYSA-N 1-[[2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1CN1CCNCC1 BCQNKADIWADQCL-UHFFFAOYSA-N 0.000 description 1
- JLYBRUBFGATRBM-UHFFFAOYSA-N 1-[[3-chloro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperazine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(Cl)=CC=CC=1CN1CCNCC1 JLYBRUBFGATRBM-UHFFFAOYSA-N 0.000 description 1
- HVDWCFNXMDSFSR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl n-[2-(naphthalen-1-ylmethylsulfanyl)phenyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1=CC=CC=C1SCC1=CC=CC2=CC=CC=C12 HVDWCFNXMDSFSR-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- DFGJILDDYSPIIG-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)-1h-imidazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NC=CN1 DFGJILDDYSPIIG-UHFFFAOYSA-N 0.000 description 1
- VBGDTCBHSKWUHT-UHFFFAOYSA-N 2-(2-benzylsulfanylphenyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C=CC=CC=1CSC1=CC=CC=C1C1=NCCN1 VBGDTCBHSKWUHT-UHFFFAOYSA-N 0.000 description 1
- UFGOFMCEZLRIJD-UHFFFAOYSA-N 2-(2-naphthalen-1-ylethyl)benzonitrile Chemical compound N#CC1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 UFGOFMCEZLRIJD-UHFFFAOYSA-N 0.000 description 1
- ORVKGXPJZJAEEK-UHFFFAOYSA-N 2-(3-aminopropylamino)-6-[(5-bromo-2-methoxyphenyl)methylsulfanyl]benzonitrile Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC(NCCCN)=C1C#N ORVKGXPJZJAEEK-UHFFFAOYSA-N 0.000 description 1
- DRZIZNYOPFSEDH-UHFFFAOYSA-N 2-(fluoromethyl)pyrimidine Chemical compound FCC1=NC=CC=N1 DRZIZNYOPFSEDH-UHFFFAOYSA-N 0.000 description 1
- BPGGBTUYXDFQIR-UHFFFAOYSA-N 2-(naphthalen-1-ylmethylsulfanyl)-3-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound C=1C=CC2=CC=CC=C2C=1CSC=1C(N)=CC=CC=1C1=NCCCN1 BPGGBTUYXDFQIR-UHFFFAOYSA-N 0.000 description 1
- VXYAUHIPEGXCOZ-UHFFFAOYSA-N 2-[(5-bromo-2-methoxyphenyl)sulfanylmethyl]benzonitrile Chemical compound COC1=CC=C(Br)C=C1SCC1=CC=CC=C1C#N VXYAUHIPEGXCOZ-UHFFFAOYSA-N 0.000 description 1
- VJKACOCRHHQFEQ-UHFFFAOYSA-N 2-[2-(naphthalen-1-ylsulfanylmethyl)phenyl]piperidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC1=CC=CC=C1C1CCCCN1 VJKACOCRHHQFEQ-UHFFFAOYSA-N 0.000 description 1
- LTWCBBRXEBVHTH-UHFFFAOYSA-N 2-[2-[(2,5-dichlorothiophen-3-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound S1C(Cl)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1Cl LTWCBBRXEBVHTH-UHFFFAOYSA-N 0.000 description 1
- FGRRSCLWFFIDDZ-UHFFFAOYSA-N 2-[2-[(2-bromo-5-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 FGRRSCLWFFIDDZ-UHFFFAOYSA-N 0.000 description 1
- PRRRRTXDJJLOLL-UHFFFAOYSA-N 2-[2-[(2-bromo-6-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=CC(Br)=C1CSC1=CC=CC=C1C1=NCCCN1 PRRRRTXDJJLOLL-UHFFFAOYSA-N 0.000 description 1
- KEDBEJDOVCGYMS-UHFFFAOYSA-N 2-[2-[(2-bromophenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound BrC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 KEDBEJDOVCGYMS-UHFFFAOYSA-N 0.000 description 1
- LTKNAMJHFJKCLP-UHFFFAOYSA-N 2-[2-[(2-chloro-6-fluorophenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC1=CC=CC(Cl)=C1CSC1=CC=CC=C1C1=NCCCN1 LTKNAMJHFJKCLP-UHFFFAOYSA-N 0.000 description 1
- VKOWVQSIVDKTFD-UHFFFAOYSA-N 2-[2-[(2-cyclopentyloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(OC2CCCC2)C=1CSC1=CC=CC=C1C1=NCCCN1 VKOWVQSIVDKTFD-UHFFFAOYSA-N 0.000 description 1
- RLQOQTQCFAZGSR-UHFFFAOYSA-N 2-[2-[(2-ethoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCOC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 RLQOQTQCFAZGSR-UHFFFAOYSA-N 0.000 description 1
- CGDASKIJYYWJSM-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-phenylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C=2C=CC=CC=2)C=C1CSC1=CC=CC=C1C1=NCCCN1 CGDASKIJYYWJSM-UHFFFAOYSA-N 0.000 description 1
- GMKOONYUECAQPJ-UHFFFAOYSA-N 2-[2-[(2-methoxy-5-thiophen-3-ylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(C2=CSC=C2)C=C1CSC1=CC=CC=C1C1=NCCCN1 GMKOONYUECAQPJ-UHFFFAOYSA-N 0.000 description 1
- JDLIHUYYNCQAES-UHFFFAOYSA-N 2-[2-[(2-methoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 JDLIHUYYNCQAES-UHFFFAOYSA-N 0.000 description 1
- NUTDJMUUFLZXSZ-UHFFFAOYSA-N 2-[2-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC1=CC=CC=C1C1=NCCCN1 NUTDJMUUFLZXSZ-UHFFFAOYSA-N 0.000 description 1
- LOPZEVFRRBDVPB-UHFFFAOYSA-N 2-[2-[(2-methylphenyl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC1=CC=CC=C1SCC1=CC=CC=C1C1=NCCCN1 LOPZEVFRRBDVPB-UHFFFAOYSA-N 0.000 description 1
- PHPOZVKYMNDMHX-UHFFFAOYSA-N 2-[2-[(2-phenylphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1CSC1=CC=CC=C1C1=NCCCN1 PHPOZVKYMNDMHX-UHFFFAOYSA-N 0.000 description 1
- MVFGKBOVQQMARR-UHFFFAOYSA-N 2-[2-[(2-propoxynaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CCCOC1=CC=C2C=CC=CC2=C1CSC1=CC=CC=C1C1=NCCCN1 MVFGKBOVQQMARR-UHFFFAOYSA-N 0.000 description 1
- PXBUAHNXIUFNNY-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methoxy]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1COC1=CC=CC=C1C1=NCCCN1 PXBUAHNXIUFNNY-UHFFFAOYSA-N 0.000 description 1
- FOVOETZPEDCAOZ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3,5-difluorophenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=C(F)C=C1C1=NCC(C)(C)N1 FOVOETZPEDCAOZ-UHFFFAOYSA-N 0.000 description 1
- XDPJOQZPTYODRK-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCCCN1 XDPJOQZPTYODRK-UHFFFAOYSA-N 0.000 description 1
- RHYDIGSQSONJBK-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NC(C)(C)CN1 RHYDIGSQSONJBK-UHFFFAOYSA-N 0.000 description 1
- RTXJBQSGOVXPQR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5,5-dimethyl-4,6-dihydro-1h-pyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC(C)(C)CN1 RTXJBQSGOVXPQR-UHFFFAOYSA-N 0.000 description 1
- OOYYKTSPPNPIOS-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5-methyl-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NC(C)CN1 OOYYKTSPPNPIOS-UHFFFAOYSA-N 0.000 description 1
- AKAKMYRPGCQWGD-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(F)C=C1C1=NCCCN1 AKAKMYRPGCQWGD-UHFFFAOYSA-N 0.000 description 1
- ZECWULPQHNOWRR-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-fluorophenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(F)C=C1C1=NCCN1 ZECWULPQHNOWRR-UHFFFAOYSA-N 0.000 description 1
- LRARSJZZXIOEEO-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-5-methylphenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(C)C=C1C1=NCCCN1 LRARSJZZXIOEEO-UHFFFAOYSA-N 0.000 description 1
- JYSMBTPEJSZMPQ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCN1 JYSMBTPEJSZMPQ-UHFFFAOYSA-N 0.000 description 1
- NYPTVDKJISWLDP-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,5-dimethyl-1,4-dihydroimidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCC(C)(C)N1 NYPTVDKJISWLDP-UHFFFAOYSA-N 0.000 description 1
- WFGIAUVZRWXFIJ-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-5,5-dimethyl-4,6-dihydro-1h-pyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCC(C)(C)CN1 WFGIAUVZRWXFIJ-UHFFFAOYSA-N 0.000 description 1
- SMZVQYVSTZGACP-UHFFFAOYSA-N 2-[2-[(5-bromo-2-methoxyphenyl)methylsulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSCC1=CC=CC=C1C1=NCCCN1 SMZVQYVSTZGACP-UHFFFAOYSA-N 0.000 description 1
- VJCWFTJNIJPWCW-UHFFFAOYSA-N 2-[2-[(5-bromo-2-propan-2-yloxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound CC(C)OC1=CC=C(Br)C=C1CSC1=CC=CC=C1C1=NCCCN1 VJCWFTJNIJPWCW-UHFFFAOYSA-N 0.000 description 1
- YOHMIPZLDKWENG-UHFFFAOYSA-N 2-[2-[(5-chloro-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Cl)C=C1CSC1=CC=CC=C1C1=NCCCN1 YOHMIPZLDKWENG-UHFFFAOYSA-N 0.000 description 1
- XAJUEBVKLILWRA-UHFFFAOYSA-N 2-[2-[(5-fluoro-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(F)C=C1CSC1=CC=CC=C1C1=NCCN1 XAJUEBVKLILWRA-UHFFFAOYSA-N 0.000 description 1
- TYHWUSYRUAHMBB-UHFFFAOYSA-N 2-[2-[(6-fluoronaphthalen-1-yl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC(F)=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 TYHWUSYRUAHMBB-UHFFFAOYSA-N 0.000 description 1
- FFFXXFREPCGSFR-UHFFFAOYSA-N 2-[2-[1-(5-bromo-2-methoxyphenyl)propan-2-yl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CC(C)C1=CC=CC=C1C1=NCCCN1 FFFXXFREPCGSFR-UHFFFAOYSA-N 0.000 description 1
- GYJLBLSVLQVQOR-UHFFFAOYSA-N 2-[2-[2-(2-methoxynaphthalen-1-yl)ethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1CCC1=CC=CC=C1C1=NCCCN1 GYJLBLSVLQVQOR-UHFFFAOYSA-N 0.000 description 1
- XDMDMDPCJLVGGW-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-chlorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(Cl)C=CC=C1C1=NCCCN1 XDMDMDPCJLVGGW-UHFFFAOYSA-N 0.000 description 1
- GPVZZAYIPVQEAG-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-fluorophenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(F)C=CC=C1C1=NCCCN1 GPVZZAYIPVQEAG-UHFFFAOYSA-N 0.000 description 1
- QMKKPQXQBBNKQM-UHFFFAOYSA-N 2-[2-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-methoxyphenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CCC1=C(OC)C=CC=C1C1=NCCCN1 QMKKPQXQBBNKQM-UHFFFAOYSA-N 0.000 description 1
- CCISHMCRIWHRTE-UHFFFAOYSA-N 2-[2-[[2,4-bis(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC=C1CSC1=CC=CC=C1C1=NCCCN1 CCISHMCRIWHRTE-UHFFFAOYSA-N 0.000 description 1
- BQGMRZMJHCNXDE-UHFFFAOYSA-N 2-[2-[[2-methoxy-5-(4-methoxyphenyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C1=CC(OC)=CC=C1C1=CC=C(OC)C(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 BQGMRZMJHCNXDE-UHFFFAOYSA-N 0.000 description 1
- RBUZILJRVMVRED-UHFFFAOYSA-N 2-[2-[[3,5-bis(trifluoromethyl)phenyl]methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CSC=2C(=CC=CC=2)C=2NCCCN=2)=C1 RBUZILJRVMVRED-UHFFFAOYSA-N 0.000 description 1
- WUPHVXHCTSWGPA-UHFFFAOYSA-N 2-[3-chloro-2-[(2-methoxynaphthalen-1-yl)sulfanylmethyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C2C=CC=CC2=C1SCC1=C(Cl)C=CC=C1C1=NCCCN1 WUPHVXHCTSWGPA-UHFFFAOYSA-N 0.000 description 1
- VSLAWUJINZENSD-UHFFFAOYSA-N 2-[3-fluoro-2-(naphthalen-1-ylmethylsulfanyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1CSC=1C(F)=CC=CC=1C1=NCCCN1 VSLAWUJINZENSD-UHFFFAOYSA-N 0.000 description 1
- XROBCDNMROGODT-UHFFFAOYSA-N 2-[3-fluoro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound C=1C=CC2=CC=CC=C2C=1SCC=1C(F)=CC=CC=1C1=NCCCN1 XROBCDNMROGODT-UHFFFAOYSA-N 0.000 description 1
- IAHONBQOZYLKBE-UHFFFAOYSA-N 2-[4-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC(Br)=CC=C1C1=NCCCN1 IAHONBQOZYLKBE-UHFFFAOYSA-N 0.000 description 1
- QQZLNBLGDXQLHB-UHFFFAOYSA-N 2-[5-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-1,4,5,6-tetrahydropyrimidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(Br)C=C1C1=NCCCN1 QQZLNBLGDXQLHB-UHFFFAOYSA-N 0.000 description 1
- QZTCPOQRAKEEBS-UHFFFAOYSA-N 2-[5-bromo-2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]-4,5-dihydro-1h-imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=C(Br)C=C1C1=NCCN1 QZTCPOQRAKEEBS-UHFFFAOYSA-N 0.000 description 1
- ZDCKTYHRUDDTRR-UHFFFAOYSA-N 2-amino-2-[2-(2-naphthalen-1-ylethyl)phenyl]acetonitrile Chemical compound N#CC(N)C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 ZDCKTYHRUDDTRR-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- YUQUNWNSQDULTI-UHFFFAOYSA-N 2-bromobenzenethiol Chemical compound SC1=CC=CC=C1Br YUQUNWNSQDULTI-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- XIMFTYYMYOBGOG-UHFFFAOYSA-N 2-hydroxy-2-(2-oxo-2-propoxyethyl)butanedioic acid Chemical compound CCCOC(=O)CC(O)(C(O)=O)CC(O)=O XIMFTYYMYOBGOG-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical group OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- WBJVPAABGFBMJQ-UHFFFAOYSA-N 2-piperazin-1-yl-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(N2CCNCC2)=N1 WBJVPAABGFBMJQ-UHFFFAOYSA-N 0.000 description 1
- SNXAPSQAOUWUBO-UHFFFAOYSA-N 3-(2-naphthalen-1-ylethyl)-2-(1,4,5,6-tetrahydropyrimidin-2-yl)aniline Chemical compound NC1=CC=CC(CCC=2C3=CC=CC=C3C=CC=2)=C1C1=NCCCN1 SNXAPSQAOUWUBO-UHFFFAOYSA-N 0.000 description 1
- QVEWNZMMZGKMOK-UHFFFAOYSA-N 3-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC2N1CCCC2 QVEWNZMMZGKMOK-UHFFFAOYSA-N 0.000 description 1
- NPCMACUQHBFXEO-UHFFFAOYSA-N 3-[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-fluorophenyl]-5,6,7,7a-tetrahydro-1h-pyrrolo[1,2-c]imidazole Chemical compound COC1=CC=C(Br)C=C1CSC1=C(F)C=CC=C1C1=NCC2N1CCC2 NPCMACUQHBFXEO-UHFFFAOYSA-N 0.000 description 1
- KGMGBTYHOQWYMB-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methoxy]pyrrolidine Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1COC1CNCC1 KGMGBTYHOQWYMB-UHFFFAOYSA-N 0.000 description 1
- VRMGVFAVTFUVOZ-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methylamino]-3-methylbutan-1-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CNC(C)(C)CCO VRMGVFAVTFUVOZ-UHFFFAOYSA-N 0.000 description 1
- YHFJHNVCVXVVEH-UHFFFAOYSA-N 3-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]phenyl]methylamino]propan-1-ol Chemical compound COC1=CC=C(Br)C=C1CSC1=CC=CC=C1CNCCCO YHFJHNVCVXVVEH-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DPFXKTGLDWZZBP-UHFFFAOYSA-N 4-(4-chlorophenyl)imidazolidine Chemical compound C1=CC(Cl)=CC=C1C1NCNC1 DPFXKTGLDWZZBP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RQCGBMCXRYEWNS-UHFFFAOYSA-N 4-[[2-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl]sulfanylmethyl]quinoline Chemical compound C=1C=NC2=CC=CC=C2C=1CSC1=CC=CC=C1C1=NCCCN1 RQCGBMCXRYEWNS-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- LCPGBTISTIGVED-UHFFFAOYSA-N 4-tert-butyl-n-(naphthalen-1-ylmethyl)-n-(2-piperidin-1-ylethyl)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N(CC=1C2=CC=CC=C2C=CC=1)CCN1CCCCC1 LCPGBTISTIGVED-UHFFFAOYSA-N 0.000 description 1
- MEAIANTWONFBMR-UHFFFAOYSA-N 5,5-dimethyl-2-[2-(2-naphthalen-1-ylethyl)phenyl]-1,4-dihydroimidazole Chemical compound N1C(C)(C)CN=C1C1=CC=CC=C1CCC1=CC=CC2=CC=CC=C12 MEAIANTWONFBMR-UHFFFAOYSA-N 0.000 description 1
- NVWMBFHESONALO-UHFFFAOYSA-N 5-bromo-2-methoxybenzenethiol Chemical compound COC1=CC=C(Br)C=C1S NVWMBFHESONALO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 101710115814 Adrenocorticotropic hormone receptor Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- TUDGFVWIANUVFB-UHFFFAOYSA-N CC1=C(C2=C(S1)C=CC=N2)C(=O)OC Chemical compound CC1=C(C2=C(S1)C=CC=N2)C(=O)OC TUDGFVWIANUVFB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical group C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100129530 Homo sapiens MC4R gene Proteins 0.000 description 1
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
- 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- HKCYUJLPMMMRCF-UHFFFAOYSA-N [1-[[2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC=C1CSC1=CC=CC2=CC=CC=C12 HKCYUJLPMMMRCF-UHFFFAOYSA-N 0.000 description 1
- XGRRFBZSVWCCNA-UHFFFAOYSA-N [1-[[3-chloro-2-(naphthalen-1-ylsulfanylmethyl)phenyl]methyl]piperidin-2-yl]methanol Chemical compound OCC1CCCCN1CC1=CC=CC(Cl)=C1CSC1=CC=CC2=CC=CC=C12 XGRRFBZSVWCCNA-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000477 aza group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical class [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- PUFRITGIUCXJFV-UHFFFAOYSA-N n,n-dimethyl-n'-(2-naphthalen-1-ylethyl)-n'-(naphthalen-1-ylmethyl)ethane-1,2-diamine Chemical compound C1=CC=C2C(CN(CCC=3C4=CC=CC=C4C=CC=3)CCN(C)C)=CC=CC2=C1 PUFRITGIUCXJFV-UHFFFAOYSA-N 0.000 description 1
- GKLFCRUTGQXRHB-UHFFFAOYSA-N n-[2-(3-bromophenyl)ethyl]-n-[(1-ethylpyrrolidin-2-yl)methyl]naphthalen-1-amine Chemical compound CCN1CCCC1CN(C=1C2=CC=CC=C2C=CC=1)CCC1=CC=CC(Br)=C1 GKLFCRUTGQXRHB-UHFFFAOYSA-N 0.000 description 1
- URCDELNWRSKOAA-UHFFFAOYSA-N n-[[2-[(5-bromo-2-methoxyphenyl)methylsulfanyl]-3-chlorophenyl]methyl]-3-(2-methylpiperidin-1-yl)propan-1-amine Chemical compound COC1=CC=C(Br)C=C1CSC1=C(Cl)C=CC=C1CNCCCN1C(C)CCCC1 URCDELNWRSKOAA-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000011234 negative regulation of signal transduction Effects 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14728899P | 1999-08-04 | 1999-08-04 | |
| US22327700P | 2000-08-03 | 2000-08-03 | |
| US60/147,288 | 2000-08-03 | ||
| US60/223,277 | 2000-08-03 | ||
| PCT/US2000/021327 WO2001010842A2 (en) | 1999-08-04 | 2000-08-04 | Melanocortin-4 receptor binding compounds and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528810A true JP2003528810A (ja) | 2003-09-30 |
| JP2003528810A5 JP2003528810A5 (enExample) | 2007-09-20 |
Family
ID=26844785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001515309A Pending JP2003528810A (ja) | 1999-08-04 | 2000-08-04 | メラノコルチン−4受容体結合化合物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1204645A2 (enExample) |
| JP (1) | JP2003528810A (enExample) |
| AU (1) | AU6621600A (enExample) |
| BR (1) | BR0012984A (enExample) |
| CA (1) | CA2381008A1 (enExample) |
| MX (1) | MXPA02001160A (enExample) |
| WO (1) | WO2001010842A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006509014A (ja) * | 2002-12-04 | 2006-03-16 | ジーン ロジック インコーポレイテッド | メラノコルチンレセプターの調節因子 |
| JP2009509912A (ja) * | 2005-06-03 | 2009-03-12 | アミカス セラピューティックス インコーポレイテッド | 肥満を治療するための薬理学的シャぺロン |
| JP2011514371A (ja) * | 2008-03-18 | 2011-05-06 | サンセラ ファーマシューティカルズ (シュバイツ) アーゲー | メラノコルチン−4受容体モジュレーターとしてのイミダゾピリミジン、イミダゾピラジン及びイミダゾピリダジン誘導体 |
| JP2022508523A (ja) * | 2018-10-01 | 2022-01-19 | ジェンザイム・コーポレーション | UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法 |
| KR102903997B1 (ko) | 2018-10-01 | 2025-12-26 | 젠자임 코포레이션 | UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법 |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002064091A2 (en) | 2001-02-13 | 2002-08-22 | Palatin Technologies, Inc. | Melanocortin metallopeptides for treatment of sexual dysfunction |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| AU766191B2 (en) | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| CA2405690A1 (en) | 2000-04-14 | 2002-10-09 | Kureha Chemical Industry Company, Limited | Nitrogen-containing compounds and antiviral drugs containing the same |
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| US20040039044A1 (en) * | 2000-10-30 | 2004-02-26 | Yuanjin Rui | Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| CN1486302A (zh) * | 2000-12-07 | 2004-03-31 | CV���ƹ�˾ | 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶 |
| WO2002062766A2 (en) * | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| PT1385823E (pt) | 2001-04-09 | 2007-01-31 | Novartis Vaccines & Diagnostic | Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4) |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| US7064139B2 (en) * | 2001-10-29 | 2006-06-20 | Uniroyal Chemical Company, Inc. | Method for treating retroviral infections |
| AU2002352878B2 (en) * | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| WO2003055873A1 (en) | 2001-12-21 | 2003-07-10 | H. Lundbeck A/S | Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
| AU2003223049A1 (en) | 2002-03-13 | 2003-09-22 | Euro-Celtique S.A. | Aryl substituted pyrimidines and the use thereof |
| DE60333937D1 (de) | 2002-05-23 | 2010-10-07 | Novartis Vaccines & Diagnostic | Substituierte quinazolinone verbindungen |
| US7396930B2 (en) | 2002-06-11 | 2008-07-08 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
| JP2004067673A (ja) * | 2002-06-11 | 2004-03-04 | Sankyo Co Ltd | 環状チオエーテル類の製造法及びその合成中間体 |
| WO2003104240A1 (ja) * | 2002-06-11 | 2003-12-18 | 三共株式会社 | 環状チオエーテル類の製造法及びその合成中間体 |
| GB2389581A (en) * | 2002-06-12 | 2003-12-17 | Viaxxel Biotech Gmbh | Hydrogenated pyrimidines and their use as inhibitors of deoxyhypusine-synthase or hypusination of eIF-5A |
| WO2004005324A2 (en) | 2002-07-09 | 2004-01-15 | Palatin Technologies, Inc. | Peptide composition for treatment of sexual dysfunction |
| JP3714948B2 (ja) | 2002-09-11 | 2005-11-09 | 呉羽化学工業株式会社 | アミン化合物及びその用途 |
| CA2503844A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| FR2852957B1 (fr) * | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
| DK1626720T3 (da) | 2003-04-04 | 2008-12-01 | Lundbeck & Co As H | 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| JP2007501861A (ja) | 2003-05-23 | 2007-02-01 | カイロン コーポレイション | Mc4−rアゴニストとしてのグアニジノ置換キナゾリノン化合物 |
| US7368453B2 (en) | 2003-11-19 | 2008-05-06 | Chiron Corporation | Quinazolinone compounds with reduced bioaccumulation |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| JP4090491B2 (ja) | 2003-12-23 | 2008-05-28 | ハー・ルンドベック・アクチエゼルスカベット | 2−(1h−インドリルスルファニル)−ベンジルアミン誘導体 |
| CA2558600C (en) | 2004-03-10 | 2013-07-09 | Kureha Corporation | A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4 |
| AR052308A1 (es) | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
| AR054393A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
| US7629473B2 (en) | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
| TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| EA020017B1 (ru) | 2009-04-30 | 2014-08-29 | Новартис Аг | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
| EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CA2899954A1 (en) | 2013-02-04 | 2014-08-07 | Merck Patent Gmbh | Positive allosteric modulators of mglur3 |
| CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016056606A1 (ja) * | 2014-10-07 | 2016-04-14 | 国立大学法人京都大学 | ベンゾイソチアゾロピリミジン誘導体またはその塩、およびウイルス感染阻害剤ならびに医薬品 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| TN2019000290A1 (en) | 2017-03-20 | 2021-05-07 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| CN108084109A (zh) * | 2017-12-21 | 2018-05-29 | 南京工业大学 | 一种2,5-二取代-1.3.4-噁二唑的合成方法 |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| EP3853234B1 (en) | 2018-09-18 | 2025-04-23 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼrの活性化 |
| BR112022004715A2 (pt) | 2019-09-19 | 2022-06-14 | Forma Therapeutics Inc | Composições de ativação de piruvato quinase r (pkr) |
| US11590209B2 (en) | 2020-01-21 | 2023-02-28 | Palatin Technologies, Inc. | Use of bremelanotide in patients with controlled hypertension |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CA3171648A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| PL4323362T3 (pl) | 2021-04-16 | 2025-08-18 | Gilead Sciences, Inc. | Sposoby wytwarzania karbanukleozydów z zastosowaniem amidów |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| JPS4920171A (enExample) * | 1972-04-22 | 1974-02-22 | ||
| US4122263A (en) * | 1973-04-11 | 1978-10-24 | Basf Aktiengesellschaft | Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides |
| JPS57122085A (en) * | 1980-12-09 | 1982-07-29 | Bayer Ag | Circulatory disease extirpenter and use |
| JPS6354369A (ja) * | 1986-08-15 | 1988-03-08 | Fujisawa Pharmaceut Co Ltd | イミダゾ−ル誘導体 |
| JPS63253073A (ja) * | 1987-04-08 | 1988-10-20 | Taisho Pharmaceut Co Ltd | 2−フエニルベンズイミダゾ−ル誘導体 |
| JPH05148197A (ja) * | 1991-05-29 | 1993-06-15 | Akzo Nv | フエノキシフエニル誘導体 |
| JPH09176871A (ja) * | 1995-12-25 | 1997-07-08 | Tamura Kaken Kk | 水溶性プリフラックス、プリント回路基板及びプリント回路基板の金属の表面処理方法 |
| US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| WO1998046243A2 (en) * | 1997-04-15 | 1998-10-22 | Csir | Pharmaceutical compositions having appetite suppressant activity |
| WO1999032482A1 (en) * | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932779A (en) * | 1996-06-10 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Screening methods for compounds useful in the regulation of body weight |
| JP2002517444A (ja) * | 1998-06-11 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としてのスピロピペリジン誘導体 |
-
2000
- 2000-08-04 JP JP2001515309A patent/JP2003528810A/ja active Pending
- 2000-08-04 CA CA002381008A patent/CA2381008A1/en not_active Abandoned
- 2000-08-04 WO PCT/US2000/021327 patent/WO2001010842A2/en not_active Ceased
- 2000-08-04 BR BR0012984-4A patent/BR0012984A/pt not_active Application Discontinuation
- 2000-08-04 MX MXPA02001160A patent/MXPA02001160A/es active IP Right Grant
- 2000-08-04 EP EP00953837A patent/EP1204645A2/en not_active Withdrawn
- 2000-08-04 AU AU66216/00A patent/AU6621600A/en not_active Abandoned
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| JPS4920171A (enExample) * | 1972-04-22 | 1974-02-22 | ||
| US4122263A (en) * | 1973-04-11 | 1978-10-24 | Basf Aktiengesellschaft | Production of 2-(o-alkylthiophenyl)-1,3-diazocycloalkene hydrohalides |
| JPS57122085A (en) * | 1980-12-09 | 1982-07-29 | Bayer Ag | Circulatory disease extirpenter and use |
| JPS6354369A (ja) * | 1986-08-15 | 1988-03-08 | Fujisawa Pharmaceut Co Ltd | イミダゾ−ル誘導体 |
| JPS63253073A (ja) * | 1987-04-08 | 1988-10-20 | Taisho Pharmaceut Co Ltd | 2−フエニルベンズイミダゾ−ル誘導体 |
| JPH05148197A (ja) * | 1991-05-29 | 1993-06-15 | Akzo Nv | フエノキシフエニル誘導体 |
| US5731408A (en) * | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| JPH09176871A (ja) * | 1995-12-25 | 1997-07-08 | Tamura Kaken Kk | 水溶性プリフラックス、プリント回路基板及びプリント回路基板の金属の表面処理方法 |
| WO1998046243A2 (en) * | 1997-04-15 | 1998-10-22 | Csir | Pharmaceutical compositions having appetite suppressant activity |
| WO1999032482A1 (en) * | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006509014A (ja) * | 2002-12-04 | 2006-03-16 | ジーン ロジック インコーポレイテッド | メラノコルチンレセプターの調節因子 |
| JP2009509912A (ja) * | 2005-06-03 | 2009-03-12 | アミカス セラピューティックス インコーポレイテッド | 肥満を治療するための薬理学的シャぺロン |
| JP2013067626A (ja) * | 2005-06-03 | 2013-04-18 | Amicus Therapeutics Inc | 肥満を治療するための薬理学的シャペロン |
| JP2011514371A (ja) * | 2008-03-18 | 2011-05-06 | サンセラ ファーマシューティカルズ (シュバイツ) アーゲー | メラノコルチン−4受容体モジュレーターとしてのイミダゾピリミジン、イミダゾピラジン及びイミダゾピリダジン誘導体 |
| JP2022508523A (ja) * | 2018-10-01 | 2022-01-19 | ジェンザイム・コーポレーション | UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法 |
| JP7545979B2 (ja) | 2018-10-01 | 2024-09-05 | ジェンザイム・コーポレーション | UDPグリコシルトランスフェラーゼ阻害剤としてのチエノ[3,2-b]ピリジン誘導体および使用の方法 |
| KR102903997B1 (ko) | 2018-10-01 | 2025-12-26 | 젠자임 코포레이션 | UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0012984A (pt) | 2002-07-16 |
| WO2001010842A3 (en) | 2001-08-16 |
| MXPA02001160A (es) | 2002-07-02 |
| CA2381008A1 (en) | 2001-02-15 |
| WO2001010842A2 (en) | 2001-02-15 |
| AU6621600A (en) | 2001-03-05 |
| EP1204645A2 (en) | 2002-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528810A (ja) | メラノコルチン−4受容体結合化合物及びその使用方法 | |
| EP1644337B1 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
| US6699873B1 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
| EP1363890A2 (en) | Melanocortin-4 receptor binding compounds and methods of use thereof | |
| TWI499416B (zh) | 作為crth2拮抗劑之吡唑化合物 | |
| AU679049B2 (en) | Antipsychotic benzimidazole derivatives | |
| JP3466265B2 (ja) | ベンゾイミダゾール化合物及び中枢神経系疾患治療薬 | |
| EP1261601B1 (de) | Substituierte indole zur modulierung von nfkb-aktivität | |
| JPH01146882A (ja) | 治療用複素環化合物 | |
| CA2373921A1 (en) | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | |
| JP2001502675A (ja) | 1―フエニル―ベンズイミダゾール化合物及びこれをbaga▲下a▼―レセプターモデュレーターとして使用する方法 | |
| EP1487821A1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| JPWO2002002533A1 (ja) | プロパン−1,3−ジオン誘導体 | |
| JP2006509014A (ja) | メラノコルチンレセプターの調節因子 | |
| BG63257B1 (bg) | Заместени пиримидинови съединения и тяхното използване | |
| US20230374143A1 (en) | A sortilin antagonist for use in the prevention or treatment of hearing loss | |
| CA2741500A1 (en) | Carbamate compound or salt thereof | |
| WO1999038849A1 (en) | PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS | |
| EP1171435A2 (de) | Pyrimidin-2-on derivate als integrinrezeptorliganden | |
| JPH05221989A (ja) | 複素環式化合物 | |
| CN101166529B (zh) | 作为大麻素受体拮抗剂的苯并三唑衍生物 | |
| US7030122B2 (en) | 1,4-disubstituted piperazine ligands for neurotransmitter receptors | |
| AU2004202804B2 (en) | Melanocortin-4 Receptor Binding Compounds and Methods of use thereof | |
| JP2002205987A (ja) | アシルアミノシクロプロパン誘導体 | |
| CN1938281A (zh) | 离子通道调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070803 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110719 |